Merck’s Enlicitide Demonstrates Efficacy in Cholesterol Trial
The pivotal CORALreef Lipids study has shown that **enlicitide decanoate**, an oral PCSK9 inhibitor developed by **Merck**, successfully met all primary and key secondary endpoints for treating hypercholesterolemia in adults…